Regentis Biomaterials develops cartilage repair solutions, with offices in Princeton, New Jersey and Or Akiva, Israel. Its core product, GelrinC, is a proprietary hydrogel invented at the Technion that is implanted as a liquid and cured in‑situ to form a resorbable implant gradually replaced by regenerated cartilage. Earlier trials in Europe and Israel showed GelrinC provided patients relief from knee pain and improved function to return to normal activities. The company closed a $15M Series D led by Haisco Pharmaceutical Group and intends to use the proceeds to conduct a pivotal clinical trial of GelrinC in the United States aimed at obtaining FDA marketing approval. As part of the investment, Haisco will serve as GelrinC's exclusive distributor in China. Regentis is led by CEO Alastair Clemow, Ph.D., and counts Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and Technion funds among its investors. Regentis Biomaterials develops GelrinC, a biodegradable implant intended to enhance growth of articular cartilage in damaged knee joints. The company is based in Or Akiva, Israel and Princeton, NJ and is led by CEO and President Dr. Alastair Clemow. GelrinC is currently an investigational device; prior pre-clinical studies demonstrated its ability to regrow cartilage. Regentis is conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of GelrinC. The company intends to use the new funding to expand clinical efforts for the implant. GelrinC is not available for sale in the U.S., Europe or Israel while clinical evaluation is ongoing.

Total raised

$25M

Funding rounds

2

Latest round

Series D

Latest activity

Feb 2016